Jacobson Pharma Corporation Ltd
HKEX:2633
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Jacobson Pharma Corporation Ltd
Research & Development
Jacobson Pharma Corporation Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
J
|
Jacobson Pharma Corporation Ltd
HKEX:2633
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
Research & Development
-$948.3k
|
CAGR 3-Years
28%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Research & Development
-¥5.9B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Research & Development
-HK$2.5B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Research & Development
-$148.3m
|
CAGR 3-Years
27%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-12%
|
|
Jacobson Pharma Corporation Ltd
Glance View
Jacobson Pharma Corp. Ltd. engages in the provision of generic drugs for both public and private sectors. The company employs 1,723 full-time employees The company went IPO on 2016-09-21. The firm runs its business via two segments. Generic Drugs segment develops, manufactures and distributes a host of off-patent medicine for various therapeutic uses. Currently the activities in this regard are primarily carried out in Hong Kong. Proprietary Chinese Medicines segment develops, manufactures and distributes Chinese medicines. Currently the activities in this regard are primarily carried out in Hong Kong.